
Policy
Latest News
Latest Videos

CME Content
More News

At a friendly debate held at the European Hematology Association 2024 Congress, hemophilia experts argued for and against wider access to gene therapy for patients living with the condition.

The arrests of the founders of Done Global, a telehealth company that provides attention-deficit/hyperactivity disorder (ADHD) medication to adults, for allegedly providing prescriptions to unqualified patients and defrauding the government have raised concerns about future access to these medications; US health care spending rose to $4.8 trillion in 2023; bipartisan legislation has been introduced to reform prior authorization with Medicare Advantage.

Ali Khawar, principal deputy assistant secretary with the Employee Benefits Security Administration (EBSA), US Department of Labor, explains how the Mental Health Parity and Addiction Equity Act (MHPAEA) aims to address the mental health crisis in the US.

The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.

FDA and the Department of Justice were criticized during a Senate hearing on the youth vaping crisis; a new COVID-19 vaccine promises easier storage and superior protection; the Supreme Court ruled to allow mifepristone to be mailed to patients without an in-person doctor’s visit.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed challenges in Duchenne muscular dystrophy (DMD) treatment access and how policy changes may support patients with DMD.

New estimations show a historic increase in health spending last year, which is projected to account for 19.7% of the gross domestic product by 2032.

At a symposium on the impact of the Inflation Reduction Act (IRA) on pharmaceutical innovation and access, speakers urged the audience to join in advocating for changes to the law.

This study reports qualitative findings from an explanatory sequential mixed-methods investigation to understand hospitals’ approaches to a novel commercial episode-based reimbursement incentive program.

Judge rules Florida's ban on gender-affirming care for minors unconstitutional; first consensus definition for long COVID aims to standardize diagnosis and care; pilot program for clinical trial diversity discontinued due to high cost and lack of impact.

During the CMS Health Equity Conference, health care leaders shared groundbreaking strategies to integrate health equity into value-based care models, aiming to enhance patient outcomes and reduce costs.

Jeff Levin-Scherz, MD, MBA, population health leader at WTW, explains that obesity care in the US is inconsistent and costly, with significant gaps across Medicare, Medicaid, and employer-based insurance.

This cross-sectional analysis of commercially insured delivering mothers suggests that greater out-of-pocket spending is incurred when pregnancy spans 2 years, causing them to face out-of-pocket limits twice.

Continuing with our Pride Month podcast series, in this episode we speak with Perry Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, and James F. Dougherty, VMD, MS, current member of Rutgers' Board of Governors.

Uninsured rates among minority groups plummeted between 2010 and 2022; Democrat lawmakers are challenging drug patents that they believe are deliberate attempts to eliminate low-cost, generic competitors; the National Institutes of Health (NIH) is piloting a nationwide network for primary care research.

During the CMS Health Equity conference, the “Implementing Health Equity Through Value-Based Care for People in Medicare” session featured a series of expert speakers who shared insights on pioneering strategies designed to advance health equity.

Initiatives that encourage or mandate collecting LGBTQ+ data could provide a plethora of benefits for clinicians and health care providers, from identifying disparities to creating stronger, more trusting relationships between LGBTQ+ patients and the health care system.

Going forward, the federal government must pay potentially hundreds of millions more to underfunded Native American tribes with health care programs; the FDA reversed its ban on Juul e-cigarettes yesterday as it reviews new court decisions and updated information; hospitals nationwide are experiencing workforce shortages as doctors and nurses increasingly leave the field.

The Bundled Payments for Care Improvement program was associated with improved quality of skilled nursing facilities in hospital referral networks for patients undergoing surgery for joint replacement.

US tuberculosis (TB) programs have helped to identify those with TB and latent TB infection and ensure they completed treatment; FDA advisers instructed that the COVID-19 vaccine Americans will receive in the fall should target the JN.1 strain; lawmakers are divided over the CMS nursing home staffing mandate.

On this episode of Managed Care Cast, Kristine Ashcraft, president and founder of YouScript, explains the importance of biomarker testing to distribute proper treatments to patients and minimize adverse events.

FDA advisers have voted against the use of MDMA as a post-traumatic stress disorder (PTSD) treatment; House members have expressed support for the 340B drug discount program but disagreed on whether it needs tighter regulation; a federal judge sided with SCAN Health Plan over CMS about incorrect 2024 Star Rating calculations.

Chief Health Equity Officer and Senior Vice President Aletha Maybank, MD, MPH, of the American Medical Association (AMA), delivered a powerful plenary session at the CMS Health Equity conference exploring the changes sparked by pivotal moments within the last 5 years.

The updated branding better reflects the group's mission of research and advocacy.

Expansion of Medicaid coverage will now include all-in-one mental health and substance use clinics; 61% of adults are estimated to have cardiovascular disease (CVD) by 2050; the FDA has taken a historic step in potential psychedelic drug approval.




































































